Contraception
RSSArticles
-
Rheumatology Association Issues Its First Reproductive Health Guidelines
The 2020 Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases is the first set of evidence-based recommendations regarding contraception and other reproductive health issues from the American College of Rheumatology.
-
Title X Final Rule Is Troubling for Providers
The recent Title X changes enacted by the Trump administration are creating major ethical dilemmas and operational challenges for family planning and reproductive health clinics nationwide.
-
Title X Problems Worsen with Recent Court Decision
The recent Title X changes have proven devastating to women depending on family planning centers for their reproductive healthcare needs. The 9th U.S. Circuit Court of Appeals ruling upheld the Trump administration’s gag rule that prohibits Title X providers from referring patients for abortion care or even answering questions about abortion.
-
How Providers Can Weather the Pandemic
As pandemic messaging moves from containment to mitigation to recovery, national experts are giving healthcare providers tips on how to weather the storm.
-
COVID-19 Shuts Down Nation; Family Planning Need Not Stop
The COVID-19 pandemic has affected every aspect of American life, including nonemergency doctor visits. But from a family reproductive health point of view, the consequences of weeks of social distancing and quarantines can present new challenges.
-
Can We Liberalize Intrauterine Device Insertion Protocols?
In this retrospective cohort study, the rate of luteal phase pregnancy was 0.4% among 239 women who did not meet pregnancy checklist criteria for intrauterine device insertion.
-
Ethics Curriculum Feasible for OB/GYN Faculty
Much ethics education focuses on students and residents, but practicing physicians also need ethics expertise. An ethics and professional curriculum was piloted for faculty in obstetrics and gynecology.
-
Testing Detects Hormone Changes Signaling Menopause
Results of a new study established that levels of anti-Müllerian hormone (AMH) can predict when a woman’s final menstrual period will occur. By measuring AMH levels, clinicians have an indicator of how many eggs a woman has remaining. The results of the research were part of the scientific evidence presented to the FDA for the 2018 approval of MenoCheck, an assay kit used to determine menopausal status in women ages 42-62 years.
-
Research Reinforces Importance of Tailoring Hormone Therapy
Data from research that examined the use of different oral and transdermal hormone therapy agents and their associations between heart fat accumulation and atherosclerosis progression indicated that in comparison to transdermal estradiol patch, oral conjugated equine estrogen appears to slow the adverse effects of increasing paracardial adipose tissue on the progression of atherosclerosis.
-
Drug Studied for Treatment of Fibroid-Associated Bleeding
Elagolix, a gonadotropin-releasing hormone antagonist currently used in the treatment of endometriosis pain, is now being studied for treatment of uterine fibroids and heavy menstrual bleeding in women. The drug was approved by the FDA in July 2018 for the treatment of moderate to severe endometriosis pain.